Immuno-PET imaging of VEGFR-2 expression in prostate cancer with ⁸⁹Zr-labeled ramucirumab.

ABSTRACT: The detection and monitoring of prostate cancer (PrCa) malignancies using most of the conventional strategies is challenging. As an over-expressed biomarker of PrCa, the vascular endothelial growth factor receptor 2 (VEGFR-2) can be delineated by non-invasive imaging to address such issue. Herein, we report the positron emission tomography (PET) of VEGFR-2 expression in a PrCa mice models by composing a novel tracer, [⁸⁹Zr]zirconium-labeled clinical VEGFR-2 antibody (Ramucirumab), i.e. ⁸⁹Zr-Df-R. The VEGFR-2 expression levels among three different PrCa cell lines (PC-3, LNCAP and LAPC-4) were confirmed by flow cytometry. The immuno-PET imaging and bio-distribution (Bio-D) study were conducted in subcutaneous PrCa mice models via the ⁸⁹Zr-Df-R. The regions o

SUBMITTER: Li M 

PROVIDER: S-EPMC6780657 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature